Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) in chronic or accelerated phase, defined as having any of the following:~  * Peripheral blood (PB) or bone marrow (BM) blasts at least 10% but less than 30%~ * PB or BM blasts and promyelocytes at least 20%~ * PB or BM basophils at least 20%~ * Progressive splenomegaly (at least 10 cm confirmed twice at least 4 weeks apart or 50% increase in splenomegaly over 4 weeks)~ * Clonal evolution defined as the presence of additional cytogenetic abnormalities other than the Ph chromosome~ * Thrombocytopenia (platelet count less than 100,000/mm\^3) unrelated to therapy~ * Hemoglobin less than 7 g/dL unrelated to therapy or bleeding~* Failed prior treatment with imatinib mesylate or intolerant, unable, or unwilling to receive it~* Ineligible for higher-priority or higher-efficacy regimens or protocols~* No blastic phase CML~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Eastern Cooperative Oncology Group (ECOG) 0-2~Life expectancy:~* At least 18 weeks~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~Renal:~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance greater than 60 mL/min~Other:~* No other concurrent illness that would preclude study entry~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No more than 2 prior cytotoxic regimens in addition to imatinib mesylate and/or hydroxyurea~* At least 4 weeks since prior chemotherapy and recovered~* Concurrent hydroxyurea and/or anagrelide allowed during first 2 courses~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 4 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* See Disease Characteristics~* See Chemotherapy~* At least 24 hours since prior imatinib mesylate~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).